Morgan Stanley analyst Sarita Kapila initiated coverage of AstraZeneca (AZN) with an Overweight rating and 14,500 GBp price target The firm sees a compelling entry point at current share levels, seeing a “reasonable valuation” ahead of AstraZeneca’s key pipeline readouts. The company offers sector leading earnings growth through fiscal 2028, the analyst tells investors in a research note. Morgan Stanley believes 2025 presents another year of double-digit earnings growth for AstraZeneca, with continued strong product sales momentum.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca Poised for Strong Growth with Strategic Market Positioning and Robust Pipeline
- AstraZeneca: Strong Growth Potential and Market Position Underpin Buy Rating
- AstraZeneca Earnings Call: Strong Growth Amid Challenges
- Trump Trade: President advocates to close carried interest tax loophole
- AstraZeneca’s Strong Financial Performance and Promising Outlook Reinforce Buy Rating